Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock
Portfolio Pulse from Benzinga Insights
Silence Therapeutics (NASDAQ:SLN) has received mixed analyst ratings over the past quarter, with a shift from bullish to somewhat bullish sentiments in the last 30 days. The average 12-month price target for SLN has increased to $60.57, reflecting a 38.45% rise from the previous target. Analysts from firms like Morgan Stanley, HC Wainwright & Co., Chardan Capital, and BMO Capital have maintained or raised their ratings and price targets, indicating a positive outlook on the company's performance despite its financial challenges, including a significant revenue decline and below-average returns on equity and assets.
April 22, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silence Therapeutics has seen a diverse range of analyst ratings, with a recent increase in its 12-month price target to $60.57, indicating a positive sentiment shift. Despite facing revenue and profitability challenges, the company's stock could benefit from the bullish outlook and target adjustments by analysts.
The increase in the average price target and the maintenance or upgrade of ratings by analysts suggest a positive short-term outlook for SLN. Despite the company's financial challenges, such as a significant revenue decline and below-average ROE and ROA, the analysts' bullish sentiments and target adjustments could drive investor interest and potentially uplift the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100